Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Dear doctors, participate in this fun and exciting quiz on direct oral anticoagulants in the treatment of venous thromboembolism. Direct oral anticoagulants (DOACs) work by directly inhibiting specific clotting factors involved in the coagulation cascade. This mechanism prevents the formation of clots in venous thromboembolism, offering an alternative to traditional anticoagulants with more predictable effects. Participate now.
1.
In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".
2.
In prostate cancer survivorship, sleep disturbances are underappreciated.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
5.
Transplantation Fails to Improve Survival in Mantle Cell Lymphoma
1.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
2.
The benefits of using magnesium sulfate during pregnancy
3.
Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025
4.
Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025
5.
The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
Recommended News For You
1.
A new theranostic drug targets different cancer types.
2.
Isatuximab Boosts MRD Negativity in Multiple Myeloma
3.
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
4.
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma
5.
In inflammatory breast cancer, ER beta regulates estrogen signaling.
Conferences That Might Interest You
Recommended Articles For You
1.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
2.
Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond
3.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
4.
Learning from Uncommon Inherited Bleeding Disorder Presentations
5.
Transformative Pathways in Oncology in Clinical Decision-Making
Boost Your Knowledge With These Quizzes
1.
Quiz on Environmental Toxins and Hormonal Cancers: Unraveling the Link
2.
Quiz On Usage Of Meropenem In Children
3.
Quiz on Peripheral Blood Smears: Can You Accurately Interpret Findings in Hemolytic Anemia?
4.
Quiz on Exploring Dermatomyositis: Symptoms, Causes, and Treatment Options
5.
Quiz On Anesthesia Drugs
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge